Oncology Practice Review – Issue 3

In this issue:
– Pembrolizumab for advanced clear-cell gynaecological cancers
– Promising new blood test to detect early pancreatic cancer
– Daratumumab delays progression from smouldering to active multiple myeloma
– Cabozantinib for advanced neuroendocrine tumours
– No benefit for PD-L1 inhibitor compared with cetuximab in platinum-ineligible patients undergoing radiotherapy for HNSCC
– Māori travel longer distances to access bronchoscopy for lung cancer
– Updated melanoma guidelines from ESMO
– Pilot study supports professional supervision to enhance job satisfaction in radiation oncology
– Pharmac funds new treatments for liver, ovarian, neuroendocrine, lung and kidney cancers
– Pharmac funds denosumab for malignant hypercalcaemia in patients with renal damage
– Change to the funded palbociclib brand
– Sonobiopsy is looking feasible for noninvasive diagnosis of brain tumours
– Antibody-drug conjugates for breast cancer: new FDA approvals and indications
– Escherichia coli as an anticancer tool?
– Gender-affirming hormone therapy and the risk of prostate cancer in transgender women